Indaptus Therapeutics Inc banner

Indaptus Therapeutics Inc
NASDAQ:INDP

Watchlist Manager
Indaptus Therapeutics Inc Logo
Indaptus Therapeutics Inc
NASDAQ:INDP
Watchlist
Price: 1.7 USD -3.41% Market Closed
Market Cap: $3.8m

During the last 3 months Indaptus Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 16% over this period (open performance analysis).

The last transaction was made on Aug 14, 2023 by Anderson Glen R. , who bought 56k USD worth of INDP shares.

Last Transactions:
Anderson Glen R.
$+2k
Anderson Glen R.
$+2.7k
Anderson Glen R.
$+3.1k
Litchev Boyan Vesselinov
$+33.7
Litchev Boyan Vesselinov
$+32.9
Meckler Jeffrey A
$+651.7
Meckler Jeffrey A
$+24.7
Meckler Jeffrey A
$+1k
Meckler Jeffrey A
$+791.6
Linscott Walt Addison
$+13.1
Meckler Jeffrey A
$+92.7
Meckler Jeffrey A
$+1.9k
Litchev Boyan Vesselinov
$+8.2
Newman Michael James
$-2.5k
Litchev Boyan Vesselinov
$+18.6
Newman Michael James
$-1.1k
Meckler Jeffrey A
$+2.3k
Meckler Jeffrey A
$+3k
View All Transactions

During the last 3 months Indaptus Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 16% over this period (open performance analysis).

The last transaction was made on Aug 14, 2023 by Anderson Glen R. , who bought 56k USD worth of INDP shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Indaptus Therapeutics Inc
Insider Trading Chart

Indaptus Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Indaptus Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Indaptus Therapeutics Inc
Glance View

Market Cap
3.8m USD
Industry
Biotechnology

Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

INDP Intrinsic Value
7.35 USD
Undervaluation 77%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett